INTRODUCTION
============

International guidelines for the treatment of chemotherapy-induced nausea and vomiting (CINV) have recommended the use of serotonin (5-hydroxytryptamine) type 3 (5-HT~3~) receptor antagonist and neurokinin-1 (NK-1) receptor antagonist and corticosteroids in patients receiving highly emetogenic chemotherapy such as cisplatin \[[@B1][@B2]\]. However, the effect of this treatment is still unsatisfactory, because the complete response rate (CR: no emesis, no rescue medication) and complete control rate (CC: CR plus no significant nausea) are reported to be only 40%--75%, and anorexia is observed about 15% of patients \[[@B3][@B4][@B5]\]. In addition, food intake has been reported to decrease to 25% of baseline by 7 days after chemotherapy that included cisplatin \[[@B6]\]. Therefore, more effective treatment for CINV and anorexia is required.

Rikkunshito, a Japanese traditional herbal medicine known as Kampo \[[@B7]\], is composed of 8 herbs (*Atractylodis lanceae rhizoma*, *Ginseng radix*, *Pinelliae tuber*, *Hoelen*, *Zizyphi fructus*, *Aurantii nobilis pericarpium*, *Glycyrrhizae radix,* and *Zingiberis rhizome*). It is widely prescribed in Japan to treat gastrointestinal disorders such as anorexia, functional dyspepsia, and gastroesophageal reflux disease \[[@B8][@B9][@B10][@B11]\]. It has been demonstrated in mice that rikkunshito ameriolates the cisplatin-induced anorexia, and flavonoids in rikkunshito antagonized 5-HT~2B~ and 5-HT~2C~ receptors \[[@B12]\].

We, therefore, designed an exploratory trial to evaluate the additive effect of rikkunshito on CINV and anorexia in patients treated with cisplatin and paclitaxel.

MATERIALS AND METHODS
=====================

1. Study design {#sec1}
---------------

This study was a multicenter, randomized phase 2 study conducted at four institutions in Hokkaido, Japan. The protocol was reviewed and approved by the Japanese Organisation for Research and Treatment of Cancer (JORTC) Protocol Review Committee and the ethical review committee of each hospital. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry as UMIN000011227.

Patients with histologically diagnosed uterine cervical or corpus cancer were eligible for inclusion if they were ≥20 years, no history of chemotherapy, and planned to receive cisplatin plus paclitaxel. They were also required to have the Eastern Cooperative Oncology Group (ECOG) performance status grade 0--2. Patients were not eligible if they suffered from brain metastasis, seizure, unconsciousness, gastrointestinal obstruction, vomiting, or nausea greater than grade 2 as described by the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0, or if they had undergone treatment within one month before enrollment with steroids, androgens, progesterones, other herbal medicines, other medicines with the potential to increase appetite, or opioids. Patients were not allowed to receive progesterones after day 0.

Enrollment and randomization were processed at the central registration center. Patients were randomized by the minimization method balancing the arms with institution and treatment (adjuvant vs. neo-adjuvant chemotherapy vs. chemotherapy only).

2. Treatment {#sec2}
------------

Patients were randomly assigned to the rikkunshito group or the control group. All patients received chemotherapy with intravenous (IV) paclitaxel 135 mg/m^2^ for 3 or 24 hours on day 0, and IV cisplatin 50 mg/m^2^ for 2 hours on day 1. They also received standard antiemetic therapy according to the Japanese antiemetic guideline of the Japan Society of Clinical Oncology \[[@B13]\]: IV granisetron 3 mg on days 0 and 1; oral aprepitant 125 mg on day 1 and 80 mg on days 2 and 3; and IV dexamethasone 9.9 mg on day 1 and 6.6 mg on days 2--4. The rikkunshito group received oral rikkunshito 7.5 g on days 0--13. It was permitted to administer paclitaxel 135 mg/m^2^ or 175 mg/m^2^ on day 1, in which case it was infused for 3 hours, and granisetron was administered only on day 1.

Rescue medication was allowed to treat refractory and persistent CINV; however, these treatments were considered treatment failure. The timing and choice of rescue treatment was decided by the investigator.

3. Assessments {#sec3}
--------------

Each patient fulfilled a diary from day 0 to day 13. The diary captured information about the timing of each emetic episode, while the severity of nausea and degree of appetite were evaluated by the patient everyday with a 100-mm visual analogue scale (VAS). The left end of the VAS (0 mm) was labeled as "no nausea", and the right end (100 mm) was labeled as "nausea as bad as it could be." A VAS score of \<5 mm was considered to indicate no nausea, and that of 5--25 mm as no significant nausea. Concomitant medications including rescue medication were referred to the medical records.

The primary efficacy endpoint was the CC rate (no emesis, no rescue medication, no significant nausea) during the overall phase (0--120 hours). Secondary endpoints were the CR rate (no emesis, no rescue medication), total control rate (no emesis, no rescue medication, and no nausea), and time to treatment failure (i.e., time to the first emetic episode or time to rescue medication) during the overall phase, the CC rate and CR rate during the acute phase (0--24 hours) and delayed phase (24--120 hours), and the VAS score from day 0 through day 13. In addition, we assessed the patient\'s quality of life (QOL) using the Quality of Life Questionnaire (QLQ)-C30 of The European Organisation for Research for Treatment of Cancer (EORTC), and their anorexia-cachexia score (ACS) using The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) on days 0, 6, and 13. We also measured serum levels of acyl ghrelin on days 0, 1, 2, 5, and 14 using an Active Ghrelin ELISA Kit (LSI Medience, Tokyo, Japan). All adverse events (AEs) and laboratory tests were graded according to the CTCAE (version 4.0) of the National Cancer Institute.

4. Statistical analysis {#sec4}
-----------------------

To calculate sample size, we assumed an overall CC rate of 75% in the rikkunshito group, and 50% in the control group. A sample size of 20 evaluable patients in each group was thus needed to ensure 60% power with a significance level of 0.2 (2-tailed) for comparison. For the primary endpoint, superiority of the rikkunshito group vs. the control group was evaluated using χ^2^ tests, with 2-tailed p\<0.200 considered to indicate a significant difference in the planned analysis. We set a significant level relatively lenient as 0.20 by considering the exploratory nature and feasibility of this study. Point estimates and 80% confidence interval (CI) of each group are calculated respectively. The difference between the groups in time to treatment failure was analyzed using Kaplan-Meier estimates and the log-rank test. Analysis was performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

RESULTS
=======

1. Patients {#sec1___1}
-----------

Forty patients were enrolled from 4 institutions from July 2013 to December 2015; 36 patients (19 in the rikkunshito group, 17 in the control group) were included in the efficacy analysis ([Fig. 1](#F1){ref-type="fig"}), and 39 patients (20 in the rikkunshito group, 19 in the control group) were included in the safety analysis. Baseline characteristics of enrolled subjects are shown in [Table 1](#T1){ref-type="table"}. Although the median age in the rikkunshito group was slightly higher than that of the control group, other baseline characteristics were comparable between the groups.

![CONSORT diagram.\
CONSORT, Consolidated Standards of Reporting Trials.](jgo-28-e44-g001){#F1}

###### Patient baseline and disease characteristics

![](jgo-28-e44-i001)

  Characteristics         Rikkunshito group (n=20)   Control group (n=20)   
  ----------------------- -------------------------- ---------------------- ------------
  Age (yr)                51.5 (14.0)                43.1 (11.1)            
  Weight (kg)             56.0 (10.9)                53.7 (7.9)             
  ECOG PS                                                                   
                          0                          19 (95.0)              20 (100.0)
                          1                          1 (5.0)                0 (0.0)
  Cancer type                                                               
                          Corpus                     3 (15.0)               2 (10.0)
                          Cervical                   17 (85.0)              18 (90.0)
  No distant metastasis   17 (85.0)                  17 (85.0)              
  No ascites              17 (85.0)                  18 (90.0)              
  Chemotherapy                                                              
                          Preoperative               9 (45.0)               10 (50.0)
                          Postoperative              9 (45.0)               8 (40.0)
                          No operation plan          2 (10.0)               2 (10.0)
  Grade of nausea                                                           
                          0                          20 (100)               20 (100)
                          1                          0                      0

Data are presented as mean (SD) or number of patients (%).

ECOG, Eastern Cooperative Oncology Group; PS, performance status; SD, standard deviation.

2. Efficacy {#sec2___1}
-----------

The primary endpoint, CC rate during the overall phase, was superior in the rikkunshito group compared to the control group (57.9% \[80% CI=43.4--72.4\] vs. 35.3% \[80% CI=20.4--50.2\]; p=0.175) ([Fig. 2](#F2){ref-type="fig"}). The CR rate during the overall phase was also superior in the rikkunshito group (84.2% \[80% CI=73.5--94.9\] vs. 52.9% \[80% CI=37.4--68.5\]; p=0.042). In addition, CC and CR rates in the delayed phase were superior in the rikkunshito group (63.2% \[80% CI=49.0--77.3\] vs. 35.3% \[80% CI=20.4--50.2\]; p=0.095, and 84.2% \[80% CI=73.5--94.9\] vs. 52.9% \[80% CI=37.4--68.5\]; p=0.042, respectively). However, the CC and CR rates in the acute phase and the total control rate in the overall phase did not differ significantly between the groups. The time to treatment failure was significantly longer in the rikkunshito group than in the control group (p=0.059, [Fig. 3](#F3){ref-type="fig"}).

![Proportion of subjects with primary and secondary endpoints. The primary endpoint was CC rate in the overall phase (0--120 hours), while others were included in the secondary endpoints. Data are presented as point estimates and 80% CI.\
CC, complete control; CI, confidence interval; CR, complete response.\
^\*^p\<0.200 from 2-tailed χ^2^ test vs. control group.](jgo-28-e44-g002){#F2}

![Kaplan-Meier plot of time to treatment failure (i.e., to first emesis or use of rescue medication).\
p=0.059 (log-rank test).](jgo-28-e44-g003){#F3}

Appetite and nausea, as assessed by VAS, appeared to be superior in the rikkunshito group from day 2 through day 6, and were comparable between the groups from day 7 through day 13 ([Fig. 4](#F4){ref-type="fig"}). Changes in serum acyl ghrelin levels were not observed after cisplatin administration in the control group; rikkunshito appeared to have no influence on serum acyl ghrelin levels ([Supplementary Table 1](#S1){ref-type="supplementary-material"}).

![VAS results for degree of appetite (A) and severity of nausea (B).\
VAS, visual analogue scale.](jgo-28-e44-g004){#F4}

The other secondary endpoints, EORTC QLQ-C30 score and FAACT ACS, did not differ significantly between the groups, although the QLQ-C30 score for nausea and vomiting appeared to be superior on day 6 in the rikkunshito group (treatment difference 9.3 points, [Supplementary Table 2](#S2){ref-type="supplementary-material"}).

3. Safety {#sec3___1}
---------

AEs were reported by 95% of subjects, and this was similar to a population receiving cisplatin ([Table 2](#T2){ref-type="table"}). The most frequent all-grade AEs for the rikkunshito and control groups were a decrease in neutrophil count, hypoalbuminemia, and nausea. Most AEs were grade 1--2, and a decrease in neutrophil count was the most frequent AE above grade 3 in both the rikkunshito and control groups. AEs were generally comparable between the groups, although the ≥grade 3 AEs of increases in alanine aminotransferase (ALT, 2 cases), aspartate aminotransferase (AST, 1 case), and gamma-glutamyl transferase (GGT, 1 case) were observed only in the rikkunshito group.

###### Summary of AEs

![](jgo-28-e44-i002)

  Events                       Rikkunshito group (n=20)   Control group (n=19)               
  ---------------------------- -------------------------- ---------------------- ----------- ----------
  Neutrophil count decreased   15 (75.0)                  8 (40.0)               9 (47.4)    8 (42.1)
  Hypoalbuminemia              15 (75.0)                  0 (0.0)                14 (73.7)   0 (0.0)
  Nausea                       13 (65.0)                  0 (0.0)                13 (68.4)   1 (5.3)
  ALT increased                12 (60.0)                  2 (10.0)               11 (57.9)   0 (0.0)
  WBC decreased                11 (55.0)                  2 (10.0)               6 (31.6)    3 (15.8)
  Hyponatremia                 11 (55.0)                  0 (0.0)                11 (57.9)   0 (0.0)
  Anorexia                     7 (35.0)                   0 (0.0)                8 (42.1)    0 (0.0)
  Hypocalcemia                 6 (30.0)                   0 (0.0)                7 (36.8)    0 (0.0)
  Malaise                      6 (30.0)                   0 (0.0)                5 (26.3)    0 (0.0)
  Constipation                 5 (25.0)                   0 (0.0)                4 (21.1)    0 (0.0)
  AST increased                4 (20.0)                   1 (5.0)                5 (26.3)    0 (0.0)
  Arthralgia                   4 (20.0)                   0 (0.0)                4 (21.1)    0 (0.0)
  ALP increased                3 (15.0)                   0 (0.0)                3 (15.8)    0 (0.0)
  Diarrhea                     3 (15.0)                   0 (0.0)                2 (10.5)    0 (0.0)
  Creatinine increased         2 (10.0)                   0 (0.0)                3 (15.8)    0 (0.0)
  Vomiting                     2 (10.0)                   0 (0.0)                2 (10.5)    0 (0.0)
  Myalgia                      2 (10.0)                   0 (0.0)                2 (10.5)    0 (0.0)
  Back pain                    2 (10.0)                   0 (0.0)                1 (5.3)     0 (0.0)
  Platelet count decreased     2 (10.0)                   0 (0.0)                1 (5.3)     0 (0.0)
  Oral mucositis               2 (10.0)                   0 (0.0)                0 (0.0)     0 (0.0)
  GGT increased                1 (5.0)                    1 (5.0)                0 (0.0)     0 (0.0)
  Abdominal pain               1 (5.0)                    0 (0.0)                3 (15.8)    0 (0.0)
  Headache                     1 (5.0)                    0 (0.0)                3 (15.8)    0 (0.0)
  Bloating                     1 (5.0)                    0 (0.0)                2 (10.5)    0 (0.0)
  Dysgeusia                    1 (5.0)                    0 (0.0)                2 (10.5)    0 (0.0)
  Hypokalemia                  1 (5.0)                    0 (0.0)                1 (5.3)     0 (0.0)
  Cheilitis                    1 (5.0)                    0 (0.0)                0 (0.0)     0 (0.0)
  Fever                        1 (5.0)                    0 (0.0)                0 (0.0)     0 (0.0)
  Dizziness                    1 (5.0)                    0 (0.0)                0 (0.0)     0 (0.0)
  Hypercalcemia                1 (5.0)                    0 (0.0)                0 (0.0)     0 (0.0)
  Allergic reaction            0 (0.0)                    0 (0.0)                1 (5.3)     0 (0.0)
  Hemoglobin increased         0 (0.0)                    0 (0.0)                1 (5.3)     0 (0.0)
  Tinnitus                     0 (0.0)                    0 (0.0)                1 (5.3)     0 (0.0)
  Hyperkalemia                 0 (0.0)                    0 (0.0)                1 (5.3)     0 (0.0)

Values are presented as number of patients (%).

AEs, adverse events; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; WBC, white blood cell.

DISCUSSION
==========

In this exploratory study, we investigated the efficacy of rikkunshito on CINV and anorexia in patients treated with cisplatin and paclitaxel. As we planned that p\<0.20 is significant in our primary analysis, CC rate during the overall phase was considered superior in the rikkunshito group compared with the control group. The rikkunshito group also showed superior results for the CC rate in the delayed phase, the CR rate in the overall and delayed phases, time to treatment failure, and the VAS scores for appetite and nausea from day 2 through day 6.

Although 5-HT~3~ receptor antagonist and NK-1 receptor antagonist are widely used for the prevention of CINV, it has been reported that other 5-HT receptors are also involved in anorexia; in animal experiments, agonists for 5-HT~2B~ and 5-HT~2C~ decreased the food intake \[[@B14][@B15]\]. Indeed, through animal experiments, it has been demonstrated that rikkunshito recovers the decrease in food intake and plasma ghrelin levels caused after cisplatin treatment, and that flavonoids in rikkunshito antagonizes the receptors for 5-HT~2B~ and 5-HT~2C~ \[[@B12]\]. Furthermore, it has been demonstrated that cisplatin suppresses the ghrelin receptor expression and ghrelin secretion in the hypothalamus through the 5-HT~2C~ receptor, and that rikkunshito attenuates this effect \[[@B16][@B17]\]. In addition, it has also been demonstrated that rikkunshito antagonizes the 5-HT~3~ receptor \[[@B18]\]. Rikkunshito may therefore have improved CINV and anorexia through an effect on these pathways.

The effect of rikkunshito on CINV and anorexia has been investigated in several clinical trials. For example, Ohno et al. \[[@B19]\] reported the results of a cross-over trial of rikkunshito in gastric cancer patients who received cisplatin and S-1: rikkunshito ameliorated the decrease in plasma acyl ghrelin levels and increased food intake, and decreased the degree of anorexia after chemotherapy. Seike et al. \[[@B20]\] also investigated the efficacy of rikkunshito in esophageal cancer patients who received cisplatin, docetaxel and 5-fluorouracil (5-FU), and showed that rikkunshito improved the CTCAE grade of nausea on day 14 and the QOL score. In the present study, serum acyl ghrelin level was not decreased after cisplatin administration in the control group, and there was great variability among the patients with no significant difference between the groups. Thus, it is possible that serum acyl ghrelin levels had already recovered on the next day after cisplatin administration, or that rikkunshito may potentiate ghrelin receptor signaling \[[@B21]\].

In this study, patients formed a highly homogeneous population; all were women, all received the same amount of cisplatin and paclitaxel, all received the same antiemetics, and the vast majority had cervical cancer. Although the CC and CR rates in our control group were relatively low compared with other studies \[[@B3][@B4][@B22][@B23]\], it has been shown that CINV is worse in women and in younger patients \[[@B24][@B25]\].

This study had limitations: the sample size was small and the study was conducted in an unblind manner. A further confirmatory study using placebo with a larger sample size is required.

In conclusion, rikkunshito significantly improved CINV and anorexia in patients who were receiving cisplatin and paclitaxel. Based on these findings, we are planning a randomized, double-blind confirmatory trial of rikkunshito for the prevention of CINV and anorexia, especially during the delayed phase.
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